Meeting Banner
Abstract #0261

Can Tumor T1 Serve as Early Response Imaging Biomarker for Neoadjuvant Chemotherapy in Osteosarcoma? A Preliminary Study

Esha Baidya Kayal1, Nikhil Sharma1, Sameer Bakhshi2, Raju Sharma3, Devasenathipathy Kandasamy3, and Amit Mehndiratta1,4
1Centre for Biomedical Engineering, Indian Institute of Technology, Delhi, New Delhi, India, 2Department of Medical Oncology, Dr. B.R. Ambedkar Institute-Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences, New Delhi, New Delhi, India, 3Radio Diagnosis, All India Institute of Medical Sciences, New Delhi, New Delhi, India, 4Department of Biomedical engineering, All India Institute of Medical Sciences, New Delhi, New Delhi, India

Histopathological examination is the current gold standard for evaluating tumor response to anti-cancer therapy; though it is possible only after surgery. Non-invasive imaging biomarkers of tumor response to therapy may be useful in optimizing existing treatments improving overall outcome. The spin-lattice relaxation time of water protons (T1) reflects therapeutic changes in tumor and is thus a generic marker of tumor response to therapy. Experimental results showed T1 relaxation time reduces upon successful chemotherapy and thus, a change in tumor T1 may be a non-invasive imaging marker of chemo-sensitivity and chemotherapy response.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here